格隆汇11月28日丨春立医疗(01858.HK)公告，北京市春立正达医疗器械股份有限公司已于2025年10月31 日发布公司2025年第三季度报告，为便于广大投资者更全面深入地了解公司2025年第三季度经营成果、 财务状况，公司计划于2025年12月8日上午10:00-11:00举行2025年第三季度业绩说明会，就投资者关心 的问题进行交流。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並表明概不就因本公告全部或任何部份內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 北 京 市 春 立 正 達 醫 療 器 械 股 份 有 限 公 司 Beijing Chunlizhengda Medical Instruments Co., Ltd.* 截至本公告日期，本公司執行董事為史文玲女士、史春寶先生、岳術俊女士及解鳳寶先生； 本公司非執行董事為王鑫先生；及本公司獨立非執行董事為徐泓女士、翁杰先生及黃德盛先生。 * 僅供識別 证券代码：688236 证券简称：春立医疗 公告编号：2025-049 （ 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ） （股 份 代 號：1858） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條由北京市春立 正達醫療器械股份有限公司（「本公司」）作出。 茲載列本公司在上海證券交易所網站刊登之《北京市春立正達醫療器械股份有 限公司關於召開2025 年第三季度業績說明會的公告》，僅供參閱。 承董事 ...

截至2025年11月28日收盘，春立医疗（688236）报收于24.46元，较前一交易日上涨0.49%，最新总市值 为93.82亿元。该股当日开盘24.56元，最高24.56元，最低23.94元，成交额达3195.81万元，换手率为 0.46%。 公司近日发布公告称，北京市春立正达医疗器械股份有限公司将于2025年12月8日上午10:00-11:00通过 上证路演中心网络互动方式召开2025年第三季度业绩说明会，介绍公司2025年第三季度经营成果及财务 状况。参会人员包括董事长史文玲、总经理史春生、财务总监卢宏悦及董事会秘书解凤宝。投资者可于 2025年12月1日至12月5日16:00前通过上证路演中心或公司邮箱ir@clzd.com提交问题。说明会结束后可 通过上证路演中心查看会议情况。 《关于召开2025年第三季度业绩说明会的公告》 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 最新公告列表 ...

| 指标 | 春立医疗 | 医疗器械行业均值 | 行业排名 | | --- | --- | --- | --- | | 总市值 | 93.82亿元 | 111.44亿元 | 38 124 | | 净资产 | 29.86亿元 | 38.93亿元 | 51 124 | | 净利润 | 1.92亿元 | 2.12亿元 | 33 124 | | 市盈率(动) | 36.74 | 57.71 | 41 124 | | 市净率 | 3.14 | 3.89 | 76 124 | | 毛利率 | 67.27% | 51.22% | 27 124 | | 净利率 | 25.34% | 9.57% | 22 124 | | ROE | 6.6% | 0.15% | 33 124 | 11月28日的资金流向数据方面，主力资金净流入290.07万元，占总成交额9.08%，游资资金净流出 229.62万元，占总成交额7.18%，散户资金净流出60.45万元，占总成交额1.89%。 近5日资金流向一览见下表： | | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净点比 散户净流入 散户净占比 | | | | | | - ...

证券代码：688236 证券简称：春立医疗 公告编号：2025-049 北京市春立正达医疗器械股份有限公司 关于召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 投资者可于 2025 年 12 月 1 日（星期一）至 12 月 5 日（星期五）16:00 前登录上证 路演中心网站首页，点击"提问预征集"栏目或通过公司邮箱 ir@clzd.com 进行提问。公 司将在说明会上对投资者普遍关注的问题进行回答。 北京市春立正达医疗器械股份有限公司（以下简称"公司"）已于 2025 年 10 月 31 日发布公司 2025 年第三季度报告，为便于广大投资者更全面深入地了解公司 2025 年第三 季度经营成果、财务状况，公司计划于 2025 年 12 月 8 日上午 10:00-11:00 举行 2025 年第 三季度业绩说明会，就投资者关心的问题进行交流。 一、 说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2025 年第三季度的经营成果及 财务指标的具体情况与投 ...

Group 1 - The core viewpoint of the news highlights the financial performance and market activity of Spring Medical, indicating a decline in stock price and notable financing activities on November 27 [1] - On November 27, Spring Medical's stock price fell by 0.69%, with a trading volume of 30.73 million yuan. The financing buy-in amount was 3.88 million yuan, while the financing repayment was 4.75 million yuan, resulting in a net financing buy of -0.87 million yuan [1] - As of November 27, the total margin balance for Spring Medical was 39.66 million yuan, accounting for 0.56% of its market capitalization, which is above the 80th percentile level over the past year, indicating a high level of financing [1] Group 2 - Spring Medical, established on February 12, 1998, and listed on December 30, 2021, specializes in the research, production, and sales of implantable orthopedic medical devices, with a primary focus on joint prosthetics and spinal implants [2] - The company's main products include hip, knee, shoulder, and elbow joint prosthetics, as well as a full range of spinal fixation systems. Its products are exported to various regions including Asia, South America, Africa, Oceania, and Europe [2] - For the period from January to September 2025, Spring Medical reported a revenue of 756 million yuan, representing a year-on-year growth of 48.75%, and a net profit attributable to shareholders of 192 million yuan, reflecting a significant increase of 213.21% [2] Group 3 - Since its A-share listing, Spring Medical has distributed a total of 359 million yuan in dividends, with 309 million yuan distributed over the past three years [3] - As of September 30, 2025, the top ten circulating shareholders of Spring Medical included new entrants such as Hong Kong Central Clearing Limited and China Europe Economic Growth Mixed Fund A, holding 2.96 million shares and 2.83 million shares respectively [3] - The eighth largest circulating shareholder, Ping An Low Carbon Economy Mixed Fund A, reduced its holdings by 1.67 million shares, while Southern Medicine Health Flexible Allocation Mixed Fund A exited the top ten circulating shareholders list [3]

Core Viewpoint - Spring Medical, a leading domestic orthopedic medical device manufacturer, focuses on the research, production, and sales of implantable orthopedic medical devices, including dental metal and invisible orthodontics, and is currently in the design inspection phase for a customized porous tantalum dental implant product [2][3] Company Overview - Spring Medical is located in Tongzhou District, Beijing, and was established on February 12, 1998, with its listing date on December 30, 2021. The company specializes in implantable orthopedic medical devices, with main products including joint prosthetics and spinal implants [7][8] - The company's product range includes joint prosthetics for hip, knee, shoulder, and elbow joints, as well as a full series of spinal internal fixation systems. Its products are exported to various regions including Asia, South America, Africa, Oceania, and Europe [8] Financial Performance - For the period from January to September 2025, Spring Medical achieved operating revenue of 756 million yuan, representing a year-on-year growth of 48.75%, and a net profit attributable to shareholders of 192 million yuan, with a year-on-year increase of 213.21% [8] - Since its A-share listing, the company has distributed a total of 359 million yuan in dividends, with 309 million yuan distributed over the past three years [8] Market Position and Recognition - Spring Medical has been recognized as a "specialized, refined, distinctive, and innovative" small giant enterprise, which is the highest honor for small and medium-sized enterprises in China, indicating its strong innovation capability and high market share [3] - The company has obtained registration certificates for hip and knee surgical robots and medical image processing software, showcasing its investment in smart medical technology [2][3] Shareholder Information - As of September 30, 2025, the top ten circulating shareholders include Hong Kong Central Clearing Limited and Central European Economic Selection Mixed A, both of which are new shareholders [9]

Group 1 - The core viewpoint of the news is that Spring Medical has shown significant financial performance with a notable increase in revenue and net profit, indicating strong growth potential in the orthopedic medical device sector [2][3] - As of September 30, 2025, Spring Medical achieved a revenue of 756 million yuan, representing a year-on-year growth of 48.75%, and a net profit attributable to shareholders of 192 million yuan, with a remarkable increase of 213.21% [2] - The company has a high financing balance of 40.53 million yuan, which accounts for 0.57% of its market capitalization, indicating a strong interest from investors [1] Group 2 - Spring Medical's main business involves the research, production, and sales of implantable orthopedic medical devices, with its primary products including joint prosthetics and spinal implants [2] - The company has distributed a total of 359 million yuan in dividends since its A-share listing, with 309 million yuan distributed over the past three years [3] - As of September 30, 2025, the number of shareholders increased by 4.12% to 6,164, while the average circulating shares per person decreased by 3.95% to 46,906 shares [2]

截至9月30日，春立医疗股东户数6164.00，较上期增加4.12%；人均流通股46906股，较上期减少 3.95%。2025年1月-9月，春立医疗实现营业收入7.56亿元，同比增长48.75%；归母净利润1.92亿元，同 比增长213.21%。 分红方面，春立医疗A股上市后累计派现3.59亿元。近三年，累计派现3.09亿元。 机构持仓方面，截止2025年9月30日，春立医疗十大流通股东中，香港中央结算有限公司位居第四大流 通股东，持股295.85万股，为新进股东。中欧景气精选混合A（020876）位居第五大流通股东，持股 283.26万股，为新进股东。平安低碳经济混合A（009878）位居第八大流通股东，持股210.00万股，相 比上期减少167.00万股。南方医药保健灵活配置混合A（000452）退出十大流通股东之列。 春立医疗今年以来股价涨95.67%，近5个交易日跌3.14%，近20日跌3.11%，近60日涨10.45%。 资料显示，北京市春立正达医疗器械股份有限公司位于北京市通州区通州经济开发区南区鑫觅西二路10 号，成立日期1998年2月12日，上市日期2021年12月30日，公司主营业务涉及北京 ...

证券之星消息，11月24日南向资金减持6.2万股春立医疗（01858.HK）。近5个交易日中，获南向资金减 持的有4天，累计净减持58.48万股。近20个交易日中，获南向资金增持的有11天，累计净增持124.27万 股。截至目前，南向资金持有春立医疗（01858.HK）4453.41万股，占公司已发行普通股的46.8%。 | 交易日 | 持股总数(股) | 持股变动(股) | 变动幅度 | | --- | --- | --- | --- | | 2025-11-24 | 4453.41万 | -6.20万 | -0.14% | | 2025-11-21 | 4459.61万 | -11.25万 | -0.25% | | 2025-11-20 | 4470.86万 | -13.03万 | -0.29% | | 2025-11-19 | 4483.88万 | -29.52万 | -0.65% | | 2025-11-18 | 4513.41万 | 1.52万 | 0.03% | 北京市春立正达医疗器械股份有限公司是一家主要从事植入性骨科医疗器械研发、生产及销售业务的中 国公司。该公司主要产品为关节假体产品及脊柱类 ...